ST-Analysis of the Fetal ECG during Intrapartum CTG Monitoring
STAN® ST - STAN® Fetal ECG ST-Analysis
3 in 1
3 Systems in 1 Unit
High Quality Intrapartum
Fetal Monitor with many
Large Touch Screen
On-Screen Review of the entire CTG recording with all events and notes
Full Keyboard function with free text notes and quick annotations
Unambiguous Colour Coded monitoring of Twin Heart Rates
- Unambiguous Colour and signal Coding for continuous Maternal Heart Rate Monitoring
Fetal ECG ST-Analysis is
unique to STAN® ST-Analysis an additional parameter which is recorded by STAN® together with the CTG and which has proven to:
Improve Fetal Outcome
Reduce Unnecessary Interventions
Reduce Fetal Blood Sampling
Increase Inter-Observer Agreement
STAN® automatically and digitally stores the entire CTG recording with all notes and provides:
Internal Digital Storage
Direct Network Archiving onto Hospital Server
Electronic Auditing of the CTG and notes
Review, Copy & e-Mail CTGs
Paperless Monitoring with no loss or fading of CTG Recordings
Evidence Based Medicine
The use of Fetal ECG ST-Analysis is supported by the Cochrane Reviewers and approved by the FDA to reduce the risk of Brain Injury during labour. STAN® also enables you to comply with the CNST Recommendations for secure long-term archiving of the CTG.
Is the only Fetal Monitor proven to reduce the risk of brain injury during labour.
STAN® S31 is a unique, one-of-a-kind, fetal monitor which combines standard CTG technology with fetal ECG ST-Analysis. The fetal ECG ST-Analysis adds a new dimension to fetal monitoring, which provides the obstetric and midwifery staff with a deeper insight into the fetal physiological reaction to events and the capability of the foetus to cope during the stress of labour and, hence, enabling the obstetric and midwifery staff to make a more informed decision on the best action to take at the time.
STAN® FECG ST-Analysis has Proven Clinical Benefits
STAN® has been developed through a long and thorough process of research and validation, and the clinical benefits are proven in large randomised controlled trials.
Results from these trials have found that using STAN® results in fewer blood samples (Fetal Blood Sampling (FBS) has been virtually eliminated in hospitals where STAN® is fully implemented), less surgical assistance and reduced incidence of metabolic acidosis at birth than conventional CTG.
STAN® FECG ST-Analysis Improves Decision Making
STAN® provides continuous analysis of the Fetal ECG and provides the user with
instantaneous information about the response of the foetus to intrapartum hypoxia.
This information can be compared to frequent Fetal Blood Sampling.
STAN® automatically displays alarms on the CTG trace to warn the user of any
abnormal Fetal ECG events, which needs to be acknowledge by the user.
Improves CTG Interpretation
STAN® improves inter-observer agreement by focusing the observer to the CTG when
Fetal ECG changes occur.
STAN® provides reassurance when intervention is not required.
STAN® FECG ST-Analysis is Safer for Baby and Mother
Using STAN® has proven to significantly reduce the rate of metabolic acidosis at birth
and a likely reduction in the incidence of neonatal encephalopathy
More Natural Births
Using STAN® has proven to give the mother a better chance of a normal spontaneous
More Timely Interventions
Using STAN® enables a more timely intervention resulting in less Caesarean Sections
and less Complicated Instrumental Deliveries
Less Fetal Blood Sampling
Using STAN® reduces the need for Fetal Blood Sampling (FBS).
FBS have been practically eliminated in hospitals where STAN® is fully implemented
STAN® Evidence Based Medicine
ST-Analysis is the analysis of changes occurring in the ST-segment of the Fetal ECG during labour.
STAN® is a fetal monitor that detects these changes in the Fetal ECG in addition to recording the CTG. The combined analysis of the CTG and Fetal ECG helps detect a foetus that is exposed to Hypoxia and which needs remedial action or delivery.